#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Testicular leiomyosarcoma Enteritis Metastatic gastric cancer Extra-osseous Ewing's sarcoma Retinoblastoma Renal cancer metastatic Epilepsy Scedosporium infection Pyruvate dehydrogenase complex deficiency Chronic lymphocytic leukaemia Progressive familial intrahepatic cholestasis Superficial vein thrombosis Cerebral amyloid angiopathy Alagille syndrome Neuroblastoma More trials…

    Learn about Rare Diseases

    Medulloblastoma recurrent – Treatment Noonan syndrome – Treatment Hereditary neuropathic amyloidosis Pulmonary fibrosis – Trials in Disease Small intestine leiomyosarcoma – Life with Disease Indolent systemic mastocytosis – Treatment Pemphigus – Trials in Disease Marginal zone lymphoma – Diagnostics Methylmalonic acidaemia – Basic Information IgA nephropathy – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Cft1946 Edg-5506 Human Coagulation Factor Vii Psma-11 Lumasiran Sodium Gluconate Fitusiran Dalbavancin Piritramide Etidronate Disodium Phleum Pratense (225) Prednisolone Sodium Phosphate Ramipril Taminadenant Lutetium (177Lu) Oxodotreotide Azd0305 Cortisone Sphingomyelin (Egg) Futibatinib Mometasone More therapies…

    Learn about Your Condition

    Muscle hypertrophy Septic shock Univentricular heart Intestinal ischaemia Hyperparathyroidism secondary Bronchiectasis Leukaemia Cervix carcinoma stage I Multiple system atrophy Obliterative bronchiolitis Ovarian epithelial cancer Vestibular disorder Cerebral amyloid angiopathy Asthma Mitral valve disease More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Clinique Victor Hugo

Clinique Victor Hugo

Centre De Cancerologie De La Sarthe, 64 Rue De Degre, Le Mans, 72000, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study Comparing Camizestrant and Palbociclib with Anastrozole and Palbociclib for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Leuprorelin Acetate
    • Palbociclib
    • Anastrozole
    Austria Belgium Bulgaria Czechia France Germany +7

  • Study of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Myelofibrosis
    Investigated Drugs:
    • ALKYLATING AGENTS
    • ANTIMETABOLITES
    • Imetelstat Sodium
    Austria Belgium Bulgaria Denmark France Germany +5

  • Study of tucatinib, pertuzumab and trastuzumab combination for patients with HER2-positive metastatic breast cancer who have brain metastases after local therapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    Investigated Drugs:
    • Fulvestrant
    • Pertuzumab
    • Anastrozole
    France

  • Study of OP-1250 for Treating Advanced or Metastatic ER+, HER2- Breast Cancer in Patients After Endocrine and CDK4/6 Inhibitor Therapy

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Fulvestrant
    • Op-1250
    • PALAZESTRANT
    Austria Belgium Bulgaria Czechia France Germany +7

  • Study of Imlunestrant, Fulvestrant, Exemestane, and Abemaciclib for Patients with Advanced Estrogen Receptor Positive, HER2 Negative Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Abemaciclib
    • Fulvestrant
    • Ly3484356
    Austria Belgium France Germany Greece Italy +2

  • Study of Niraparib and Dostarlimab Combined with Platinum Therapy for Newly Diagnosed Stage III or IV Non-mucinous Epithelial Ovarian Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Dostarlimab
    • Niraparib Tosilate Monohydrate
    Belgium Czechia Denmark Finland France Germany +7

  • Study on Chemotherapy with Cisplatin, Fluorouracil, and Docetaxel for Patients with Locally Advanced Squamous Cell Carcinoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Metastatic squamous cell carcinoma
    Investigated Drugs:
    • Cisplatin
    • Docetaxel
    • Fluorouracil
    France

  • Study of Trastuzumab Deruxtecan with or without Pertuzumab for Patients with HER2-positive Metastatic Breast Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Pertuzumab
    • Trastuzumab Deruxtecan
    • Docetaxel
    Belgium Denmark France Germany Hungary Italy +3

  • Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with Advanced HER2-Positive Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • HER2 positive breast cancer
    Investigated Drugs:
    • Trastuzumab Deruxtecan
    • Trastuzumab Emtansine
    Belgium France Italy Spain

  • Study on Eye Health During Treatment with Mirvetuximab Soravtansine, Brimonidine Tartrate, and Prednisolone Acetate for Patients with Recurrent Ovarian Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Ovarian cancer
    Investigated Drugs:
    • Brimonidine Tartrate
    • Mirvetuximab Soravtansine
    • Prednisolone Acetate
    Belgium France Ireland Spain
Previous Page
1 … 5 6 7 8 9
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!